ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1228

Estimating Under-Diagnosis of Rheumatoid Arthritis in Primary Care Data from the UK Clinical Practice Research Datalink

Julian Gardiner1, Bowen Su1, Benjamin Ellis2 and Michael Soljak1, 1Department of Primary Care and Public Health, Imperial College London, London, United Kingdom, 2Arthritis Research UK, London, United Kingdom

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Diagnostic criteria, Electronic Health Record, epidemiologic methods and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Epidemiology and Public Health Poster II: Pathogenesis and Treatment of Systemic Inflammatory Diseases

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

The prevalence of rheumatoid arthritis (RA) in primary care electronic health records (EHRs) is much lower than patient self-reports from population surveys, which may be due to under-diagnosis. The objectives of this study were to identify possible RA cases using a diagnostic algorithm developed from the 2010 EULAR/ACR criteria, and to compare them with EHR RA diagnosis cases, in order to estimate potential under-diagnosis rates.

Methods:

Patients’ EHRs in the UK Clinical Practice Research Datalink (CPRD) contain diagnostic, clinical and test information. We extracted relevant data to identify patients with diagnosed RA and possible additional RA cases using an algorithm consisting of four parts, including joint involvement and symptom duration, acute phase reactants, and serology tests. Clinical findings, diagnostic labels and results of tests ordered by consultant rheumatologists are not available in CPRD. In the EULAR/ACR classification criteria patients can score up to five points for any joint involvement, up to three points for positive serology, one point for positive acute phase reactants and one point if the duration of symptoms is greater than six weeks. In line with the classification criteria we defined those with a score of six or more as “algorithm-diagnosed RA cases”. The incidence of RA was calculated from the number of CPRD patients receiving a new RA diagnosis in that year divided by the denominator. The prevalence was calculated from the cumulative number of patients receiving an RA diagnosis up to and including a given year (as far back as CPRD records allow, with patients who have died being removed).

Results:

A total of 88,299 patients had a primary care EHR diagnosis of RA, and an additional 12,928 were defined as algorithm-diagnosed RA cases. The prevalence of RA was 0.49% for EHR-diagnosed RA, rising to 0.58% if algorithm diagnosed cases are included (Table 1.). This has risen steadily over time, possibly because of more complete diagnostic coding. The incidence of EHR-diagnosed RA is approximately 30.4/100,000 over the period 2005-14 compared with 6.0/100,000 algorithm-diagnosed cases, an overall incidence rate of 36.4/100,000. There were 3,091 patients diagnosed by both a doctor and the algorithm. The mean age of EHR-diagnosis patients was 60.2 years compared with 57.7 years for the algorithm-diagnosis group, which may suggest diagnostic delay.

Table 1. Incidence and prevalence of RA in the CPRD. Figures are per 100,000 people.

Year

Incidence of doctor diagnosed RA

Incidence of algorithm diagnosed RA

Total incidence of RA

Prevalence of doctor diagnosed RA

Prevalence of algorithm diagnosed RA

Total prevalence of RA

Denominator

2000

21.16

4.55

25.71

220.46

18.65

239.12

11,915,756

2001

24.19

5.29

29.48

236.13

23.89

260.02

11,982,172

2002

24.99

5.94

30.93

252.24

29.63

281.86

12,042,662

2003

27.10

7.13

34.22

269.58

36.47

306.05

12,096,190

2004

31.78

6.96

38.74

290.88

42.94

333.82

12,151,149

2005

30.49

6.92

37.41

310.31

49.56

359.87

12,204,412

2006

29.50

6.67

36.17

329.37

55.67

385.03

12,258,669

2007

28.40

6.43

34.84

346.74

61.35

408.09

12,311,226

2008

27.83

7.12

34.95

363.32

67.65

430.97

12,363,171

2009

28.15

6.37

34.52

380.32

73.05

453.37

12,411,546

2010

25.79

6.14

31.93

394.83

78.38

473.21

12,457,701

2011

25.96

5.65

31.60

409.49

83.02

492.51

12,499,758

2012

27.90

5.50

33.40

427.27

87.48

514.75

12,535,602

2013

38.84

4.87

43.71

455.23

91.19

546.42

12,563,940

2014

41.01

4.10

45.11

487.74

94.21

581.94

12,585,816

Conclusion:

The algorithm developed from the 2010 ACR/EULAR criteria identified a significant number of possible RA cases, or patients who may be at high risk of developing RA, in addition to those with a coded diagnosis. Insufficiently accurate coding of joint involvement by general practitioners prevented more precise scoring and classification. Delayed or under-diagnosis has implications for prognosis in these patients.


Disclosure: J. Gardiner, None; B. Su, None; B. Ellis, None; M. Soljak, None.

To cite this abstract in AMA style:

Gardiner J, Su B, Ellis B, Soljak M. Estimating Under-Diagnosis of Rheumatoid Arthritis in Primary Care Data from the UK Clinical Practice Research Datalink [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/estimating-under-diagnosis-of-rheumatoid-arthritis-in-primary-care-data-from-the-uk-clinical-practice-research-datalink/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/estimating-under-diagnosis-of-rheumatoid-arthritis-in-primary-care-data-from-the-uk-clinical-practice-research-datalink/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology